Suven Life Sciences Ltd (SUVEN)
🎯 Key Takeaways
- Suven Life Sciences is in a high-investment clinical development phase, transitioning from early-stage operations to late-stage biopharmaceutical commercialization. The company is burning cash as it advances multiple Phase 3 clinical trials and expands its global footprint, including plans for a Singapore subsidiary.
- Revenue grew 134.9% QoQ to ₹4 in Q1FY27.
- ⚠️ 1) Persistent cash burn and reliance on capital markets for funding pose execution and dilution risks. 2) Clinical trial timelines are critical — dela
📖 The Story
Suven Life Sciences is in a high-investment clinical development phase, transitioning from early-stage operations to late-stage biopharmaceutical commercialization. The company is burning cash as it advances multiple Phase 3 clinical trials and expands its global footprint, including plans for a Singapore subsidiary. Despite current losses, it maintains a debt-free balance sheet and strong promoter holding, signaling long-term commitment to R&D-driven growth.
📰 What's Happening
In Q1 FY2026, Suven reported a consolidated net loss of ₹1,276.46 lakhs and EPS of (4.84), driven by heavy R&D and operational expenditures. The board approved a preferential issue of convertible warrants raising ₹85,764.02 lakhs and reallocated unused CAPEX funds toward clinical development. Key clinical milestones include initiating Phase 3 of SUVN-G3031 in April 2026 and completing SUVN-502 patient enrollment by September 2026. The company also reappointed key directors and approved a senior executive appointment in overseas subsidiaries with USD 400,000 remuneration.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1 | 3 | 2 | 4 |
| Operating Profit | -81 | -105 | -52 | -135 |
| OPM % | -8814.1% | -3726.0% | -3435.5% | -3772.0% |
| Net Profit | -77 | -102 | -46 | -128 |
| EPS | ₹-3.48 | ₹-4.55 | ₹-2.02 | ₹-4.84 |
Revenue remains minimal, with quarterly top lines hovering around ₹1-4 crores, but operating losses have widened significantly, reaching ₹128 lakhs in Q1 FY2026. The negative operating margins (-3772%) reflect heavy investment in clinical trials and global expansion. Despite the losses, cash inflows from the preferential issue and no borrowings support liquidity, while asset growth indicates strategic investments in infrastructure and intellectual property.
🔮 Management Outlook & What's Next
Management is focused on advancing its clinical pipeline, particularly SUVN-502 and SUVN-G3031, with clear milestones tied to Phase 3 completion by September 2026. There is active capital reallocation from CAPEX to clinical development, supported by auditor oversight via CRISIL. Management also emphasizes governance updates, shareholder communication, and global regulatory positioning as part of long-term commercialization strategy.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 22 | 22 | 23 | 26 |
| Reserves | 171 | 88 | 259 | 410 |
| Borrowings | 0 | 0 | 0 | 0 |
| Total Liabilities | 212 | 135 | 337 | 624 |
| Fixed Assets | 25 | 59 | 58 | 73 |
| Investments | 74 | 22 | 247 | 181 |
| Total Assets | 212 | 135 | 337 | 624 |
The balance sheet remains conservative with zero debt and modest equity growth, indicating no leverage risk. Total assets have grown from ₹135 lakhs to ₹624 lakhs over two years, reflecting investments in reserves and intangible assets. Equity and reserves have steadily increased, suggesting capital preservation and reinvestment of proceeds from warrant issues and operations.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | -300 |
| Investing | -462 |
| Financing | +757 |
| Net Cash Flow | -5 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 67.4% | 70.2% | 70.1% |
| FII | 1.1% | 0.9% | 0.6% |
| DII | 3.4% | 4.6% | 2.9% |
| Public | 22.3% | 19.4% | 21.4% |
| # Shareholders | 64,381 | 63,915 | 66,791 |
Promoter holding remains stable near 70%, with slight increases in FII and DII allocations over recent quarters, indicating growing institutional interest. The shareholder base has expanded to over 66,000 investors, suggesting rising retail participation. No pledging or significant dilution from warrant conversions has occurred yet, and the recent reappointment of independent directors signals governance continuity.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 61.0 | 22.1% | 22.9% | 0.60 |
| MANIPALHOS | 1.00 L Cr | — | — | — | 1.25 |
| MAXHEALTH | 99,174 | 68.0 | 14.4% | 13.6% | 0.27 |
| FORTIS | 68,550 | 65.4 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 65,881 | 122.3 | 17.2% | 11.9% | 0.21 |
| MEDANTA | 39,854 | 71.6 | 21.9% | 16.3% | 0.10 |
| NH | 38,979 | 47.5 | 13.7% | 18.0% | 1.07 |
| LALPATHLAB | 32,521 | 46.8 | 29.6% | 21.8% | 0.00 |
| KIMS | 31,685 | 147.9 | 9.7% | 8.7% | 1.44 |
| POLYMED | 17,871 | 56.7 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent cash burn and reliance on capital markets for funding pose execution and dilution risks. 2) Clinical trial timelines are critical — delays in SUVN-502 or SUVN-G3031 could impact revenue potential. 3) Minimal revenue base makes performance highly dependent on regulatory approvals and commercial launch timelines. 4) Related party transactions, such as overseas executive compensation, require close monitoring for governance compliance.
📋 Recent Filings
-
Announcement 11 August 2026Suven Life Sciences disclosed a CRISIL Monitoring Agency Report for the quarter ended June 30, 2026, confirming compliance with utilization of proceed...
-
🟡 Board Meeting 6 August 2026Suven Life Sciences announced unaudited standalone and consolidated financial results for Q1 FY2026, showing a consolidated net loss of ₹1,276.46 lakh...
-
🔴 annual report 30 July 2026Suven Life Sciences disclosed that its FY2025-26 Annual Report is accessible via its website at https://www.suven.com/annualreports.aspx, urging share...
-
🔴 annual report 30 July 2026Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026 via video conference, approving the adoption of FY2025-26 audited financia...
-
Announcement 14 July 2026Suven Life Sciences announced an upcoming investor and analyst meeting in Mumbai on July 17, 2026, to discuss its business outlook and financial perfo...
-
🟡 Board Meeting 8 July 2026Suven Life Sciences approved the conversion of 1,85,70,133 fully paid warrants into equity shares at ₹134 per share, allotting the same to 17 non-prom...
-
share transfer 8 July 2026Suven Life Sciences received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming compliance with demateri...
-
Financial Results 26 June 2026Suven Life Sciences announced that its trading window will close on July 1, 2026, until 48 hours after the un-audited Q1 results are declared, with th...
-
Announcement 22 June 2026Suven Life Sciences announced its participation in the BIO International Convention 2026 in San Diego from June 22-25, where it will showcase its CNS ...
-
🔴 Corporate Action 22 June 2026Suven Life Sciences approved the allotment of 271,970 equity shares at Rs 55 per share upon exercise of vested options under its 2020 ESOP, increasing...
🧠 Analyst's Read
Suven is a high-risk, long-term clinical play with no near-term revenue visibility, but its debt-free structure and focused R&D pipeline offer potential upside if clinical milestones are met. Investors should watch for updates on SUVN-502 enrollment completion and regulatory progress in H2 2026, which could catalyze re-rating.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SUVEN files new disclosures
Track SUVEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SUVEN — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd